Respiratory Disease Research: Multi-Modal Biospecimen Approaches

Featured Image Credit: https://phil.cdc.gov/ – Respiratory tissue inflammation (Public Domain)

---

Blood-Based Approaches to Respiratory Disease Investigation

Respiratory diseases including chronic obstructive pulmonary disease, asthma, interstitial lung diseases, and acute respiratory infections affect millions across the United States. Understanding disease mechanisms, identifying biomarkers, and developing therapeutics require integrated investigation of systemic and local immune responses alongside inflammatory mediators circulating in blood.

Plasma, serum, peripheral blood mononuclear cells, and whole blood provide accessible windows into respiratory disease biology. Inflammatory markers correlate with disease severity. Immune cell phenotypes predict exacerbation risk. Gene expression signatures classify disease endotypes.

The natural history of chronic respiratory diseases spans decades. COPD develops through progressive airflow obstruction. Asthma exhibits variable airflow limitation punctuated by exacerbations. Pulmonary fibrosis can involve progressive scarring and declining gas exchange. Each condition follows distinct trajectories that benefit from longitudinal biospecimen collections capturing molecular and cellular evolution over time.

From study design through receipt of samples collected under standardized conditions, proper biospecimen selection enables blood-based respiratory disease investigation. Researchers across academic pulmonary centers and pharmaceutical organizations require high-quality specimens with comprehensive genomic annotation supporting reproducibility and translational relevance.

Chronic Obstructive Pulmonary Disease Biomarkers

COPD affects over 16 million diagnosed individuals across the United States, with millions more undiagnosed. Chronic bronchitis and emphysema result from cigarette smoking, environmental exposures, and genetic susceptibility including alpha-1 antitrypsin deficiency. Progressive airflow limitation occurs alongside systemic inflammation that contributes to cardiovascular disease, osteoporosis, and muscle wasting comorbidities.

Plasma inflammatory markers including C-reactive protein, fibrinogen, and interleukin-6 are commonly elevated in COPD and can correlate with disease severity and decline in lung function. CRP elevations are associated with increased exacerbation risk, while fibrinogen has been investigated as a prognostic marker in clinical trial enrichment strategies.

Surfactant protein D measured in serum reflects alveolar epithelial injury and emphysema severity in multiple study contexts. Club cell secretory protein may decrease in COPD, reflecting airway epithelial damage. These lung-associated proteins complement systemic inflammatory readouts, supporting multi-modal biomarker panels that capture both pulmonary and systemic aspects of disease.

PBMC gene expression profiling has identified COPD-associated transcriptional signatures involving inflammatory pathway activation, oxidative stress response changes, and epigenetic regulatory features consistent with long-term smoke exposure. Endotypes such as emphysema-predominant versus chronic bronchitis phenotypes may show distinct molecular profiles that can guide stratification in precision medicine studies.

Asthma Inflammation and Biomarker Profiling

Asthma affects over 25 million individuals across the United States and is characterized by airway hyperresponsiveness, inflammation, and variable, often reversible obstruction. Type 2 inflammation driven by Th2 lymphocytes, eosinophils, and cytokines such as IL-4, IL-5, and IL-13 is common in allergic asthma. Non-type 2 inflammation can involve neutrophilic or mixed inflammatory patterns and is often associated with treatment-refractory severe disease.

Serum IgE quantification supports identification of allergic asthma, including elevated total IgE and allergen-specific IgE responses. IgE-mediated mast cell activation drives acute bronchoconstriction and contributes to chronic airway remodeling through repeated inflammatory cycles.

Peripheral blood eosinophil counts derived from whole blood are commonly used to estimate exacerbation risk and guide biologic therapy selection. Thresholds such as 150–300 eosinophils/μL are frequently used in clinical trial designs and real-world practice to enrich for type 2 inflammation, recognizing that context and treatment status can influence interpretation.

Plasma periostin and other circulating markers have been studied as indicators of IL-13-driven epithelial activation. While biomarker performance can vary by assay and population, these measurements can contribute to endotyping frameworks when integrated with clinical features and additional immune readouts.

PBMC transcriptomics can distinguish asthma molecular phenotypes beyond the type 2 versus non-type 2 dichotomy. Gene expression patterns may reveal interferon-associated signatures, mitochondrial and metabolic remodeling, or proliferative and activation states, informing pathway-targeted therapeutic hypotheses.

Essential Quality Specifications for Respiratory Research Biospecimens

When sourcing blood biospecimens for respiratory disease studies, researchers should verify collection context and phenotype definition to prevent confounding and support reproducibility.

Respiratory Function Documentation

• Spirometry results including FEV1, FVC, and FEV1/FVC ratio
• Bronchodilator reversibility testing differentiating asthma from fixed obstruction
• DLCO measurements for interstitial lung disease and emphysema context
• Six-minute walk distance or other functional capacity measures
• Chest imaging findings (CT or X-ray) describing structural changes
• Disease severity classifications (e.g., GOLD stages, GINA steps)

Clinical Phenotype Characterization

• Symptom scores (CAT for COPD, ACT for asthma) at the time of collection
• Exacerbation history, including frequency and severity over the prior year
• Smoking status and pack-year history (and vaping or biomass exposure where relevant)
• Allergen sensitization profiles in allergic asthma
• Medication regimen including inhaled corticosteroids, biologics, systemic steroids
• Treatment response patterns supporting refractory versus controlled phenotypes
• Comorbidities including cardiovascular disease and metabolic conditions

Sample Collection Variables

• Stable-state versus exacerbation sampling context, which can shift inflammatory profiles
• Medication timing relative to blood draw (e.g., pre- versus post-inhaler)
• Time since last exacerbation influencing baseline biomarker interpretation
• Seasonal effects in allergic asthma, including pollen and viral exposure patterns
• Air quality and environmental triggers at collection
• Recent viral infections that may confound chronic inflammatory measurements

Processing Quality Standards

• Plasma separated within 2 hours to minimize cellular release artifacts
• Serum clotted ~30 minutes at room temperature before centrifugation
• PBMCs isolated within 8 hours maintaining viability targets (commonly >85%)
• Whole blood collected in appropriate tubes when transcriptomics are planned
• Immediate –80°C storage for protein and nucleic acid stability
• Aliquoting strategies limiting freeze–thaw cycles to preserve analyte integrity

Key Research Variables in Respiratory Biospecimen Studies

Investigators analyzing respiratory biomarkers across diverse U.S. populations should account for disease heterogeneity, environmental exposures, and treatment effects. These variables influence immune phenotypes, circulating protein signatures, and longitudinal kinetics.

Disease Heterogeneity Factors

• COPD includes emphysema versus chronic bronchitis phenotypes with distinct biology
• Asthma includes allergic, eosinophilic, neutrophilic, and paucigranulocytic endotypes
• Overlap syndromes (e.g., asthma-COPD overlap) with mixed clinical features
• Rapid versus slow disease progression requiring stratification
• Frequent versus infrequent exacerbators representing distinct pathophysiology

Environmental and Lifestyle Influences

• Geographic location influencing allergen exposures and air quality
• Occupational exposures to dusts, fumes, and chemicals contributing to disease
• Secondhand smoke exposure in never-smokers with respiratory disease
• Climate factors affecting seasonal exacerbation patterns
• Urban versus rural residence correlating with pollution and exposure profiles
• Housing quality affecting mold, dampness, and indoor air triggers

Treatment Impact on Biomarkers

• Inhaled corticosteroids influencing systemic and cellular inflammatory signals
• Biologic therapies altering pathway-specific biomarkers and immune cell distributions
• Systemic corticosteroids during exacerbations profoundly affecting measurements
• Smoking cessation altering inflammatory parameters over time
• Supplemental oxygen and advanced disease affecting metabolic measures

Sanguine Bio’s Comprehensive Respiratory Research Support

Respiratory disease investigations present unique biospecimen challenges, including variability driven by environmental exposures, exacerbation timing, and treatment effects. Sanguine Bio’s direct-to-donor model and expanded donor network provide access to well-characterized patient populations across diverse geographic regions throughout the United States, supporting environmental and demographic diversity essential for generalizable findings.

Custom collection services accommodate respiratory-specific requirements. We coordinate stable-state versus exacerbation sampling when feasible. We document medication timing, exposure histories, and clinical phenotype definitions to enrich genomic annotation. From study design through receipt of samples, comprehensive support helps ensure respiratory research validity and downstream analytical consistency.

Access to hard-to-find populations includes treatment-naïve COPD cohorts prior to long-term therapy initiation, severe asthma populations with multi-therapy failure, rare interstitial lung disease subtypes, and longitudinal cohorts capturing natural history progression. These specialized capabilities enable studies that are difficult to execute through standard procurement channels.

Respiratory & Metabolic Conditions Biospecimens provides a centralized entry point to explore respiratory-focused biospecimen solutions supporting COPD, asthma, and other lung disease programs.

Ethical Sourcing and Compliance Standards

All respiratory disease biospecimens are ethically sourced under institutional review board approval with informed consent. Participant privacy protections follow HIPAA requirements with de-identification practices designed to prevent individual identification while preserving research utility.

Quality management systems maintain comprehensive documentation supporting regulatory compliance. Collection protocols follow standard operating procedures. Trained personnel perform venipuncture and processing under validated conditions. Storage and shipping maintain biospecimen integrity and traceability.

Check Our Inventory for available respiratory disease biospecimens or contact us to discuss custom collection services matching your research requirements across geographic regions of the United States.

Advancing Respiratory Medicine Through Blood-Based Research

Blood biospecimens provide scalable, minimally invasive windows into respiratory disease pathology, enabling biomarker discovery, therapeutic monitoring, and mechanistic investigation across diverse patient populations. Integration of plasma inflammatory markers, serum protein measurements, PBMC immunophenotyping, and whole blood transcriptomics supports multi-modal molecular profiling aligned to precision respiratory medicine objectives.

From study design through receipt of samples collected under optimized conditions with comprehensive genomic annotation, proper biospecimen selection accelerates respiratory research translating discoveries into improved outcomes for millions affected by lung diseases across the United States.

---

References

1. Agusti A, et al. Systemic effects of chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2005;2(4):367-370. https://doi.org/10.1513/pats.200504-026SR
2. Brightling CE, et al. Sputum eosinophilia and the short term response to inhaled mometasone in chronic obstructive pulmonary disease. Thorax. 2005;60(3):193-198. https://doi.org/10.1136/thx.2004.032516
3. Chung KF, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43(2):343-373. https://doi.org/10.1183/09031936.00202013
4. Dickens JA, et al. Defining and characterizing bronchiectasis in alpha-1 antitrypsin deficiency. BMC Pulm Med. 2017;17(1):194. https://doi.org/10.1186/s12890-017-0543-0
5. Fingerlin TE, et al. Genome-wide association study identifies multiple susceptibility loci for pulmonary fibrosis. Nat Genet. 2013;45(6):613-620. https://doi.org/10.1038/ng.2609
6. Gibson PG, et al. Heterogeneity of airway inflammation in persistent asthma. Am J Respir Crit Care Med. 2001;164(10 Pt 1):1778-1783. https://doi.org/10.1164/ajrccm.164.10.2011049
7. Haldar P, et al. Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med. 2008;178(3):218-224. https://doi.org/10.1164/rccm.200711-1754OC
8. Hilaire RC, et al. Plasma proteomics reveals tissue-specific cell death and mediators of cell-cell interactions in severe COVID-19 patients. Nat Commun. 2020;11(1):6256. https://doi.org/10.1038/s41467-020-20204-y
9. Jatakanon A, et al. Neutrophilic inflammation in severe persistent asthma. Am J Respir Crit Care Med. 1999;160(5 Pt 1):1532-1539. https://doi.org/10.1164/ajrccm.160.5.9806170
10. Oczypok EA, et al. Pulmonary receptor for advanced glycation end-products promotes asthma pathogenesis. J Allergy Clin Immunol. 2015;136(3):747-756. https://doi.org/10.1016/j.jaci.2015.03.011
11. Papi A, et al. Asthma. Lancet. 2018;391(10122):783-800. https://doi.org/10.1016/S0140-6736(17)33311-1
12. Sin DD, et al. Biomarkers in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2006;173(5):490-491. https://doi.org/10.1164/rccm.200510-1628PP
13. Silkoff PE, et al. ATS/ERS recommendations for measurement of exhaled nitric oxide. Am J Respir Crit Care Med. 2005;171(8):912-930. https://doi.org/10.1164/rccm.200406-710ST
14. Woodruff PG, et al. T-helper type 2-driven inflammation defines subphenotypes of asthma. Am J Respir Crit Care Med. 2009;180(5):388-395. https://doi.org/10.1164/rccm.200903-0392OC
15. Yokokawa T, et al. Elevated exhaled nitric oxide in chronic obstructive pulmonary disease: systematic review and meta-analysis. Resp Res. 2018;19(1):169. https://doi.org/10.1186/s12931-018-0869-x